Esperion Therapeutics (ESPR) Expected to Announce Earnings on Thursday

Key Points

• Esperion is scheduled to report Q1 2026 results before the market opens on May 7, 2026, with analysts forecasting ($0.04) EPS and $94.875 million in revenue and a conference call at 8:00 AM ET.
• In the most recent quarter the company slightly missed EPS estimates (reported $0.22 vs. $0.23 expected) while beating revenue ($168.45M vs. $165.12M), and analysts now project $0 EPS for the current and next fiscal years.
• The stock opened at $1.91 (12‑month range $0.69–$4.18) with a market cap of about $492M and ~47% institutional ownership, and the Street’s consensus rating is a “Moderate Buy” with a $8.75 price target.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) is expected to issue its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.04) per share and revenue of $94.8750 million for the quarter. Individuals can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last released its earnings results on Tuesday, March 10th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing analysts' consensus estimates of $0.23 by ($0.01). The business had revenue of $168.45 million for the quarter, compared to analysts' expectations of $165.12 million. On average, analysts expect Esperion Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.91 on Thursday. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $4.18. The stock has a 50-day simple moving average of $2.58 and a 200 day simple moving average of $3.08. The company has a market capitalization of $491.64 million, a PE ratio of -11.24, a P/E/G ratio of 1.55 and a beta of 1.17.

Institutional Investors Weigh In On Esperion Therapeutics

Several institutional investors have recently bought and sold shares of the company. Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics during the 2nd quarter worth approximately $25,000. Kestra Advisory Services LLC bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth $35,000. Captrust Financial Advisors bought a new stake in shares of Esperion Therapeutics in the fourth quarter worth $40,000. CIBC Bancorp USA Inc. acquired a new position in Esperion Therapeutics during the third quarter worth $56,000. Finally, Cibc World Markets Corp acquired a new position in Esperion Therapeutics during the fourth quarter worth $57,000. Institutional investors own 47.39% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ESPR. Citizens Jmp increased their target price on Esperion Therapeutics from $4.00 to $5.00 and gave the stock a "market outperform" rating in a research note on Friday, March 13th. Wall Street Zen raised shares of Esperion Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. HC Wainwright restated a "buy" rating on shares of Esperion Therapeutics in a report on Tuesday, March 10th. Finally, Needham & Company LLC boosted their price objective on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Tuesday, March 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.75.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company's research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company's lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.